Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTOR Phase II Colorectal Cancer Master Protocol
2024-518469-84-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing volrustomig + chemotherapy + bevacizumab with chemotherapy + bevacizumab (standard of care) (2 arms). Primary endpoints: Incidence and severity of adverse events and serious adverse events, Change from baseline in safety parameters and 1 more. Planned start Jun 2025; status: authorised.
02
Drugs
volrustomig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-518469-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518469-84-00.